Beta Bloker Zehirlenmeleri

Yazarlar

Cüneyt Arıkan

Özet

Beta blokerler; supraventriküler disritmiler, hipertansiyon, miyokard enfarktüsü ve kalp yetmezliği gibi kardiyovasküler hastalıkların tedavisinde yaygın olarak kullanılan, güçlü ve hızlı etkili ilaçlardır. Uygunsuz kullanımlarında veya aşırı doz alımlarında kalsiyum kanal blokerlerinin ardından en sık zehirlenmeye yol açan kardiyovasküler ilaç grubu olup klinik tabloda sıklıkla bradikardi, hipotansiyon, nörolojik bulgular ve hipoglisemi gözlenir. Patofizyolojik olarak adrenerjik reseptörlerin yarışmalı inhibisyonu, kalsiyumun hücre içine girişini engelleyerek kardiyak iletimi ve kasılma gücünü azaltır. Ayrıca sodyum kanal blokajı (geniş QRS kompleksi), yüksek lipofilik özellik (santral sinir sistemi depresyonu ve nöbetler) veya alfa-adrenerjik blokaj gibi ilaca özgü özellikleri klinik zehirlenme tablosunun seyrini ve ciddiyetini doğrudan etkiler. Tanıda vital bulguların monitörizasyonu, 12 derivasyonlu EKG, kan gazı analizi, laktat, glukoz takibi ve yatak başı ekokardiyografi büyük önem taşır. Tedavinin temel amacı organ perfüzyonunu korumak ve miyokardiyal disfonksiyonu düzeltmektir. Başlangıçta havayolu ve dolaşım desteklenerek IV sıvı ve atropin verilir; orta ve ağır toksisitelerde IV kalsiyum, glukagon, yüksek doz insülin öglisemi tedavisi, vasopresörler (norepinefrin/epinefrin), geniş QRS durumunda sodyum bikarbonat ve inatçı vakalarda IV lipid emülsiyonu uygulanır. Dirençli olgularda ise kalp pili, hemodiyaliz ve ECMO gündeme gelebilir. Normal salınımlı ilaç alımından 6 saat sonra asemptomatik kalan hastalar taburcu edilebilirken, uzun salımlı ilaç alanlar ile hemodinamik instabilitesi olan hastaların yoğun bakım ünitesinde takibi gereklidir.

Beta-blockers are potent and rapid-acting medications widely used in the treatment of cardiovascular diseases such as supraventricular dysrhythmias, hypertension, myocardial infarction, and heart failure. In cases of improper use or overdose, they represent the second most common cause of cardiovascular drug poisoning after calcium channel blockers, with clinical presentations most frequently featuring bradycardia, hypotension, neurological symptoms, and hypoglycemia. Pathophysiologically, competitive inhibition of adrenergic receptors impairs intracellular calcium entry, thereby reducing cardiac conduction and contractility. Furthermore, drug-specific properties such as sodium channel blockade (wide QRS complex), high lipophilicity (central nervous system depression and seizures), or alpha-adrenergic blockade directly influence the clinical course and severity of toxicity. Diagnosis relies heavily on vital sign monitoring, 12-lead ECG, blood gas analysis, lactate and glucose monitoring, and bedside echocardiography. The primary goal of treatment is to maintain organ perfusion and reverse myocardial dysfunction. Initial management includes airway and circulatory support alongside IV fluids and atropine; moderate to severe toxicities require IV calcium, glucagon, high-dose insulin euglycemic therapy, vasopressors (norepinephrine/epinephrine), sodium bicarbonate for QRS prolongation, and IV lipid emulsion for refractory cases. Pacemaker placement, hemodialysis, and ECMO may be considered in resistant cases. While patients remaining asymptomatic 6 hours post-ingestion of standard-release preparations can be discharged, those taking extended-release formulations or presenting with hemodynamic instability require intensive care unit monitoring.

Referanslar

Walls RM, Hockberger RS, Gausche-Hill M. Rosen’s Emergency Medicine: Concepts and Clinical Practice, (Ninth edition). (2018) Philadelphia: Elsevier

Cruickshank JM. Are we misunderstanding beta-blockers. Int J Cardiol. 2007;120(1):10-27. doi:10.1016/j.ijcard.2007.01.069

Wax PM, Erdman AR, Chyka PA, et al. Beta-blocker ingestion: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila). 2005;43(3):131-146.

Gummin DD, Mowry JB, Beuhler MC, et al. 2019 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 37th Annual Report. Clin Toxicol (Phila). 2020;58(12):1360-1541. doi:10.1080/15563650.2020.1834219

Menke NB, Walsh SJ, King AM. Cardiotoxicodynamics: Toxicity of Cardiovascular Xenobiotics. Emerg Med Clin North Am. 2015;33(3):563-595. doi:10.1016/j.emc.2015.04.007

Rotella JA, Greene SL, Koutsogiannis Z, et al. Treatment for beta-blocker poisoning: a systematic review. Clin Toxicol (Phila). 2020;58(10):943-983. doi:10.1080/15563650.2020.1752918

Tintinalli JE. (2020). Tintinalli's Emergency Medicine A Comprehensive Study Guide (Ninth edition) New York: McGraw Hill Medical Books

DeWitt CR, Waksman JC. Pharmacology, pathophysiology and management of calcium channel blocker and beta-blocker toxicity. Toxicol Rev. 2004;23(4):223-238. doi:10.2165/00139709-200423040-00003

Kline JA, Leonova E, Raymond RM. Beneficial myocardial metabolic effects of insulin during verapamil toxicity in the anesthetized canine. Crit Care Med. 1995;23(7):1251-1263. doi:10.1097/00003246-199507000-00016

Khalid MM, Galuska MA, Hamilton RJ. Beta-Blocker Toxicity. In: StatPearls. Treasure Island (FL): StatPearls Publishing; November 21, 2020.

Kerns W 2nd. Management of beta-adrenergic blocker and calcium channel antagonist toxicity. Emerg Med Clin North Am. 2007;25(2):309-viii. doi:10.1016/j.emc.2007.02.001

Love JN, Enlow B, Howell JM, et al. Electrocardiographic changes associated with beta-blocker toxicity. Ann Emerg Med. 2002;40(6):603-610. doi:10.1067/mem.2002.129829

Mladěnka P, Applová L, Patočka J, et al. Comprehensive review of cardiovascular toxicity of drugs and related agents. Med Res Rev. 2018;38(4):1332-1403. doi:10.1002/med.21476 Fung HT, Lai CH, Wong OF, et al. The use of glucagon and other antidotes in a case of beta-blocker and calcium channel blocker overdose. Hong Kong J Emerg Med. 2007;14(2):113–118.

Cole JB, Stellpflug SJ, Ellsworth H, et al. A blinded, randomized, controlled trial of three doses of high-dose insulin in poison-induced cardiogenic shock [published correction appears in Clin Toxicol (Phila). 2013 Dec;51(10):1246]. Clin Toxicol (Phila). 2013;51(4):201-207. doi:10.3109/15563650.2013.770152

Mégarbane B, Karyo S, Baud FJ. The role of insulin and glucose (hyperinsulinaemia/euglycaemia) therapy in acute calcium channel antagonist and beta-blocker poisoning. Toxicol Rev. 2004;23(4):215-222. doi:10.2165/00139709-200423040-00002

Palatnick W, Jelic T. Emergency department management of calcium-channel blocker, beta blocker, and digoxin toxicity. Emerg Med Pract. 2014;16(2):1-20.

Gunja N, Graudins A. Management of cardiac arrest following poisoning. Emerg Med Australas. 2011;23(1):16-22. doi:10.1111/j.1742-6723.2010.01369.x

Levine M, Skolnik AB, Ruha AM, et al. Complications following antidotal use of intravenous lipid emulsion therapy. J Med Toxicol. 2014;10(1):10-14. doi:10.1007/s13181-013-0356-1

Kerns W 2nd, Kline J, Ford MD. Beta-blocker and calcium channel blocker toxicity. Emerg Med Clin North Am. 1994;12(2):365-390.

Hayes BD, Gosselin S, Calello DP, et al. Systematic review of clinical adverse events reported after acute intravenous lipid emulsion administration. Clin Toxicol (Phila). 2016;54(5):365-404. doi:10.3109/15563650.2016.1151528

Vignesh C, Kumar M, Venkataraman R, et al. Extracorporeal Membrane Oxygenation in Drug Overdose: A Clinical Case Series. Indian J Crit Care Med. 2018;22(2):111-115. doi:10.4103/ijccm.IJCCM_417_17

İndir

Yayınlanan

6 Nisan 2021

Lisans

Lisans